Femasys (Femasys) Debt-to-Asset : 0.28 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Femasys Debt-to-Asset?

Femasys's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.50 Mil. Femasys's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.38 Mil. Femasys's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $24.37 Mil. Femasys's debt to asset for the quarter that ended in Mar. 2024 was 0.28.

Femasys Debt-to-Asset Historical Data

The historical data trend for Femasys's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys Debt-to-Asset Chart

Femasys Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.14

0.27

0.04

0.03

0.24

Femasys Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													0.02	0.02	0.19	0.24	0.28

Competitive Comparison of Femasys's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Femasys's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Femasys's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Femasys's Debt-to-Asset falls into.

Femasys Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Femasys's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.407	+	6.294)	/	27.756
	=	0.24

Femasys's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.495	+	6.375)	/	24.371
	=	0.28

Femasys (NAS:FEMY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Femasys Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Femasys's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Femasys (Femasys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024

Website

https://www.femasys.com

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Executives

Keith J Kendall	director	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes	director	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas	officer: SVP, Regulatory & Clinical	2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash	officer: Chief Medical Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett	director, 10 percent owner	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr	director	35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko	director, 10 percent owner	4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen	director	28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick	director, officer: Chief Executive Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie	officer: Senior VP, Operations	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria	officer: VP, Clinical & Medical Affairs	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson	director	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte	director	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025